Результаты поиска

Is the Scope of Costs Considered in Budget Impact Analyses for Anticancer Drugs Rational? A Systematic Review and Comparative Study.

Background: With the increasing disease burden of cancer worldwide, more and more anticancer drugs have been approved in many countries, and the results of budget impact analyses (BIAs) have become important evidence for related reimbursement decisions. Objectives: We systematically reviewed whether BIAs for anticancer drugs consider the scope of costs rationally and compared the results of different cost scopes to provide suggestions for future analyses and decision-making. Methods: Eligible BIAs published in PubMed, Embase, Web of Science, and the Cochrane Library from 2016 to 2021 were iden

Excess Body Weight and the Risk of Second Primary Cancers Among Cancer Survivors.

ImportanceLittle is known about the causes of second primary cancers among individuals with a history of cancer. Descriptive studies have suggested that lifestyle factors, including excess body weight, may be important.ObjectiveTo investigate whether excess body weight is associated with the risk of a second primary malignant neoplasm among cancer survivors.Design, setting, and participantsThis cohort study of adults in 21 states in the US used data from the Cancer Prevention Study II Nutrition cohort, a large prospective study that invited participants to respond to a survey in 1992 and bienn

Hospitalization at the end of life in patients with multiple myeloma.

BACKGROUND: Despite advances in treatment, multiple myeloma (MM) remains incurable and results in significant morbidity and mortality. Further research investigating where MM patients die and characterization of end-of-life hospitalizations is needed. METHODS: We utilized the National Inpatient Sample (NIS) to explore the hospitalization burden of MM patients at the end of their lives. RESULTS: The percent of patients dying in the hospital as a percent of overall MM deaths ranged from 54% in 2002 to 41.4% in 2017 (p < 0.01). Blood transfusions were received in 32.7% of these hospitalizations

Comparison of Access to Novel Drugs for Lymphoma and Chronic Lymphocytic Leukemia Between India and the United States.

This review will compare and contrast the costs and access to novel drugs for treating chronic lymphocytic leukemia (CLL) and lymphoma in the United States and India during the last 5 years. Clinical outcomes for patients with hematologic malignancies have improved significantly since the approval of immunotherapeutic and targeted therapies. These new treatments have had an impact on overall outcomes and have helped determine the design for translational research and future trials. Although most of these novel drugs called "innovators" are initially approved and marketed in the United States,

Phase-specific and lifetime costs of cancer care in Ontario, Canada.

BackgroundCancer is a major public health issue and represents a significant economic burden to health care systems worldwide. The objective of this analysis was to estimate phase-specific, 5-year and lifetime net costs for the 21 most prevalent cancer sites, and remaining tumour sites combined, in Ontario, Canada.MethodsWe selected all adult patients diagnosed with a primary cancer between 1997 and 2007, with valid ICD-O site and histology codes, and who survived 30 days or more after diagnosis, from the Ontario Cancer Registry (N = 394,092). Patients were linked to treatment data from Cancer

Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination.

Bispecific antibodies (BsAbs) have emerged as crucial therapeutic agents for patients with relapsed/refractory diffuse large B-cell lymphoma, multiple myeloma, and most recently, lung cancer. These therapies have demonstrated remarkable efficacy in clinical trials; however, multidisciplinary collaboration is essential to ensure optimal patient outcomes amid the operational complexities associated with BsAb therapy. As BsAbs are being prepared for broader adoption, clinicians and treatment centers must navigate operational challenges, including financial considerations, patient selection, careg

Facing financial barriers to healthcare: patient-informed adaptation of a conceptual framework for adults with a history of cancer.

BackgroundCancer-related financial hardship is associated with negative clinical outcomes, which may be partially explained by cost-related delayed or forgone care in response to financial barriers. We sought to understand patient experiences facing financial barriers to medical care following a cancer diagnosis.MethodsWe conducted virtual, semi-structured interviews in Fall 2022 with 20 adults with a history of cancer who had experienced cancer-related financial hardship in the prior year. We used template analysis within a pragmatic paradigm, combining constructivist and critical realist the

The current socioeconomic and regulatory landscape of immune effector cell therapies.

Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent a transformative approach to cancer treatment, harnessing the immune system to target and eradicate malignant cells. CAR-T cell therapy, the most established among these, involves engineering T cells to express CARs specific to cancer cell antigens, showing remarkable efficacy in hematologic malignancies like leukemias, B-cell lymphomas, and multiple myeloma. Similarly, TCR-modified therapies, which reprogram T ce

Depressed, anxious and breathless missing out: Weight screening in general practice in a regional catchment of New South Wales.

ObjectiveTo assess the recording status of weight management measures among adults presenting to general practices within regional catchments.DesignCross-sectional; secondary data analysis.SettingPrimary health care - 17 general practices located in the Illawarra Shoalhaven region of regional New South Wales.ParticipantsA subset of the Sentinel Practices Data Sourcing project database (n = 118 709 adults) that included information on demographic indicators, chronic disease status, and obesity and overweight-specific measurement indicators recorded from September 2011 to September 2013.Main out

Association between race and treatment patterns and survival outcomes in multiple myeloma: A Connect MM Registry analysis.

BackgroundStudies have reported racial disparities in access to and use of multiple myeloma (MM) treatments between African American (AA) and White patients. Although AA patients demonstrate longer disease-specific survival, this has not uniformly translated into improved survival over time. The association between race and treatment patterns and survival outcomes was analyzed using data from the Connect MM Registry.MethodsThe Connect MM Registry is a large US, multicenter, prospective observational cohort study of patients with newly diagnosed MM. Patients who received first-line (1L) stem ce

Contemporary treatment patterns of overweight and obesity: insights from the Mass General Brigham health care system.

ObjectiveThe objective of this study was to describe the prevalence of obesity, obesity-related conditions (ORCs), and antiobesity medication (AOM) eligibility and prescribing practice among eligible patients in a large health care system.MethodsIn this cross-sectional analysis of the multicenter Mass General Brigham health care system (Boston, Massachusetts) spanning 2018 to 2022, adults eligible for AOMs (BMI ≥ 30 kg/m2 or BMI 27-29.9 kg/m2 with ≥1 ORC) were identified. Among those AOM-eligible, the prevalence of prescriptions for AOMs approved for long-term weight management was evaluated.R

Совпадение в полном тексте источника
… As it has been well‐established that Medicare excluded coverage of pharmacotherapy to support weight reduction over the study interval (Medicare Part D coverage has since been expanded to include semaglutide 2.4 mg among adults with overweight and obesity and established cardiovascular disease) [ 35 … Medicare Part D coverage of antiobesity medications ‐ challenges and uncertainty ahead . N Engl J Med . 2023 ; 388 : 961 ‐ 963 . 36912541 10.1056/NEJMp2300516 36 FDA news release. …

Evaluation of Emergency Department Visits by Oncology Patients: A Running Comparison to Admissions and ED Visits Under the CMS OP-35 Ruling.

BackgroundCancer is the second leading cause of death in the United States. The incidence of emergency department (ED) visits by oncology patients has grown over the past years. Some ED visits are medically unnecessary and could be prevented with improved prevention measures.ObjectivesTo evaluate the incidence and causes of ED visits by cancer patients and evaluate outcomes and disposition of ED visits.MethodsThis single-center, retrospective chart review was conducted in a tertiary medical hospital. We collected data using an electronic medical record and included oncology patients with activ

Value-based pricing: Toward achieving a balance between individual and population gains in health benefits.

ObjectivesValue-based pricing of oncology drugs provides a best estimate for the price of a drug, as it relates to the benefits it provides for individual patients. To date, the impact of value-based pricing to reference cost-effectiveness thresholds (λ) on individual and population-level health benefits remains uncharacterized. The current study examined the potential benefits of value-based pricing by quantifying the incremental net health benefit (INHB) of publicly funded oncology drugs, if funding occurred at manufacturer-submitted price without value-based pricing.MethodsPan-Canadian Onco

Factors influencing cancer patients' experiences of care in the USA, United Kingdom, and Canada: A systematic review.

The extent to which individual and structural factors influence cancer patients' reports of their experiences are not yet well understood. We sought to identify which groups of patients consistently report poorer experiences and whether structural care factors might also be associated with better or worse reports. We conducted a systematic review of literature in PubMed and Web of Science with the date of last search as 27th of February 2022 following PRISMA guidelines. We focused on studies from three established population-based surveys datasets and instruments. After screening 303 reference

Impact of Social Needs and Identity Experiences on the Burden of Illness in Patients with Multiple Myeloma: A Mixed-Methods Study.

Multiple myeloma (MM) is a common hematologic malignancy, but due to its incurable nature, patients experience many relapses in their lifetime and hence face unique challenges. This mixed-methods study consisting of an online survey and subsequent focus groups aimed to understand how social and identity experiences affected the diagnostic, treatment, and care journey for patients with MM. Twenty-three adult patients with MM participated in this study. The survey participants identified common determinants negatively impacting their health, including mental health concerns (experienced by 90.5%

Abstracts From JADPRO Live at APSHO 2017.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Trends in overall survival and costs of multiple myeloma, 2000-2014.

Little real-world evidence is available to describe the recent trends in treatment costs and outcomes for patients with multiple myeloma (MM). Using the Truven Health MarketScan Research Databases linked with social security administration death records, this study found that the percentage of MM patients using novel therapy continuously increased from 8.7% in 2000 to 61.3% in 2014. Compared with MM patients diagnosed in earlier years, those diagnosed after 2010 had higher rates of novel therapy use and better survival outcomes; patients diagnosed in 2012 were 1.25 times more likely to survive

Abstracts from the 5th PPRI conference 2024: ensuring access to affordable medicines through innovative policies, Vienna, Austria, 25–26 April 2024

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Реальная эффективность вакцины против рекомбинантного зостера ≥50- Взрослые, страдающие аутоиммунными заболеваниями.

СПРАВОЧНАЯ ИНФОРМАЦИЯ: Данные реального мира об эффективности вакцины (ВЭ) прилегающей рекомбинантной вакцины от зостера (ВЗВ) для предотвращения герпеса зостера (ВЗ) у лиц с аутоиммунными заболеваниями (АИД) ограничены. Для устранения этого пробела в знаниях мы намеревались провести оценку VE 2 Дозы RZV против HZ в ≥50- взрослые в возрасте от одного года с отобранными АИД (ремуматоидный артрит, воспалительный кишечник, системный волшебный эритематос, множественный склероз (MS), псориаз (PsO) и псориатический артрит). Мы провели ретроспективное когортное исследование с использованием деидентиф

Совпадение в полном тексте источника
… These findings align with those from a cohort study involving ≥65-year-old Medicare Part D beneficiaries with AIDs, which reported HZ IRs of 4.4/1000 person-years for 2-dose RZV-vaccinated individuals and 14.9/1000 person-years for unvaccinated individuals and a 2-dose RZV VE of 68.0% (95% CI: 62.3; … This VE is consistent with the previously estimated 57.7% VE for a 1-dose regimen among ≥65-year-old Medicare Part D community-dwelling beneficiaries with AIDs [ 19 ]. …

Leveraging stories of cardiac amyloidosis patients of African ancestry or descent to support patient-derived data elements for efficient diagnosis and treatment.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.